Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

ARS Pharmaceuticals (SPRY) Leases (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Leases for 5 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • Quarterly Leases rose 1464.13% to $1.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Sep 2025, up 1464.13% year-over-year, with the annual reading at $37000.0 for FY2024, 85.2% down from the prior year.
  • Leases hit $1.4 million in Q3 2025 for ARS Pharmaceuticals, down from $1.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $5.0 million in Q3 2021 to a low of $37000.0 in Q4 2024.
  • Historically, Leases has averaged $1.3 million across 5 years, with a median of $421500.0 in 2022.
  • Biggest five-year swings in Leases: plummeted 91.12% in 2023 and later skyrocketed 1464.13% in 2025.
  • Year by year, Leases stood at $621000.0 in 2021, then fell by 28.34% to $445000.0 in 2022, then plummeted by 43.82% to $250000.0 in 2023, then plummeted by 85.2% to $37000.0 in 2024, then soared by 3789.19% to $1.4 million in 2025.
  • Business Quant data shows Leases for SPRY at $1.4 million in Q3 2025, $1.6 million in Q2 2025, and $72000.0 in Q1 2025.